Completion↦Quality and Risk↦Clinical Study Report↦Risk Reporting
What is it? Why is it important?
A (final) Clinical Study Report (CSR) is an account describing in detail the methods, events and results of a study. The reporting of the risk management of the study is an important integral part of this document.
The CSR is written after the monitoring close-out visit has taken place, as the study is then closed and ready for the statistical analysis. Among other the report describes:
- The risk-based QMS implemented during the study
- Identified risks including applicable control measures
- Important deviations and remedial actions taken
The SP-INV submits the final CSR to the Ethics Committee (EC) and RA (e.g. Swissmedic), as applicable.
What do I need to do?
Based on the RAF:
- Describe the risk-based QMS implemented in your study
- Summarise important deviations and remedial actions taken
- If you have been audited include the audit certificate
- Complete other report sections and submit the report to the EC and RA (e.g. Swissmedic), as applicable
The CSR must be ready and submitted to the EC no later than 1 year the completion (last visit of the last participant) or discontinuation of the study.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R2) – see in particular guidelines
- 1.6 Audit
- 5.0 Quality management
ISO 9001 (access liable to costs – see in particular section
- QMS Requirements
Swiss Law
ClinO – see in particular article
- Art 38 Final report